Murine anti-idiotype antibody 3H1

Abstract

The present invention provides a monoclonal anti-idiotype antibody 3H1 that escapes immune tolerance and elicits a specific immune response to CEA in mice, rabbits, monkeys, and patients with advanced CEA-associated disease. This invention also provides compositions which can be used in the detection or treatment of CEA-associated tumors mimics a specific epitope on carcinoembryonic antigen and a hybridoma that produces 3H1.

What is claimed is:  
     
         1 . A monoclonal anti-idiotype antibody 3H1 produced by a hybridoma cell line ATCC No. HB12003 and progeny thereof.  
     
     
         2 . The antibody of    claim 1   , further comprising a label capable of producing a detectable signal.  
     
     
         3 . A hybridoma cell line designated ATCC No. HB12003 and progeny thereof.  
     
     
         4 . A hybridoma cell line that produces a monoclonal anti-idiotype antibody having a light chain variable region amino acid sequence identical to SEQ ID NO:2 and a heavy chain variable region amino acid sequence identical to SEQ ID NO:4.  
     
     
         5 . A monoclonal anti-idiotype antibody having a light chain variable region amino acid sequence identical to SEQ ID NO:2 and a heavy chain variable region amino acid sequence identical to SEQ ID NO:4.  
     
     
         6 . A monoclonal anti-idiotype antibody having a light chain variable region encoded by a polynucleotide encoding an amino acid sequence identical to SEQ. ID. NO:2 and a heavy chain variable region encoded by a polynucleotide encoding an amino acid sequence identical to SEQ. ID NO:4.  
     
     
         7 . A pharmaceutical composition comprising an effective amount of monoclonal anti-idiotype antibody 3H1 in a pharmaceutically acceptable excipient.  
     
     
         8 . A vaccine comprising an effective amount of monoclonal anti-idiotype antibody 3H1.  
     
     
         9 . The vaccine of    claim 8   , further comprising an adjuvant.  
     
     
         10 . The vaccine of    claim 9   , wherein the adjuvant is aluminum hydroxide.  
     
     
         11 . A method of eliciting an immune response in an individual with advanced carcinoembryonic antigen (CEA) associated disease comprising the step of administering an effective amount of monoclonal anti-idiotype antibody 3H1 to the individual.  
     
     
         12 . The method of    claim 11   , wherein the immune response is the production of anti-CEA antibody.  
     
     
         13 . A method of eliciting an immune response in an individual with advanced CEA-associated disease comprising the step of administering the vaccine of    claim 9    to the individual.  
     
     
         14 . The method of    claim 13   , wherein the immune response is the production of anti-carcinoembryonic antigen.  
     
     
         15 . A method for detecting the presence of an anti-CEA antibody bound to a tumor cell comprising the steps of contacting the tumor cell with monoclonal antibody according to    claim 1    for a sufficient time to allow binding to the anti-CEA antibody, and detecting the presence of any 3H1 which is bound to the anti-CEA antibody.  
     
     
         16 . A method for detecting the presence of an anti-CEA antibody bound to a tumor cell comprising the steps of contacting the tumor cell with the monoclonal anti-idiotype antibody according to    claim 5    for a sufficient time to allow binding to the anti-CEA antibody, and detecting the presence of any 3H1 which is bound to the anti-CEA antibody.  
     
     
         17 . A diagnostic kit for detection or quantitation of an anti-carcinoembryonic antigen antibody comprising a monoclonal anti-idiotype antibody according to    claim 1    in suitable packaging.  
     
     
         18 . A diagnostic kit for detection or quantitation of an anti-carcinoembryonic antigen antibody comprising a monoclonal anti-idiotype antibody according to    claim 5    in suitable packaging.  
     
     
         19 . A method for detecting an anti-carcinoembryonic antigen response in an individual comprising contacting a biological sample from the individual with the monoclonal antibody of    claim 1   .  
     
     
         20 . A method for detecting an anti-carcinoembryonic antigen response in an individual comprising contacting a biological sample from the individual with the monoclonal anti-idiotype antibody of    claim 5   .  
     
     
         21 . A method of palliating carcinoembryonic antigen-associated disease in an individual having advanced carcinoembryonic antigen-associated disease comprising administering an effective amount of monoclonal antibody 3H1 to the individual.